1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Positive Phase IIb data from AstraZeneca in lupus and RA but PhIII not assured

 
• By Sukaina Virji

AstraZeneca's MedImmune unit has presented positive Phase IIb data at the American College of Rheumatology (ACR) meeting this week from two products highlighted by CEO Pascal Soriot as 'ones to watch' as he fended off Pfizer's unwanted advances earlier this year (scripintelligence.com, 28 May 2014). However, their progress into Phase III is not assured as AstraZeneca is waiting on data from other trials before making a decision on how to proceed.

AstraZeneca's MedImmune unit has presented positive Phase IIb data at the American College of Rheumatology (ACR) meeting this week from two products highlighted by CEO Pascal Soriot as 'ones to watch' as he fended off Pfizer's unwanted advances earlier this year (scripintelligence.com, 28 May 2014). However, their progress into Phase III is not assured as AstraZeneca is waiting on data from other trials before making a decision on how to proceed.

Sifalimumab (MEDI-545), a monoclonal antibody targeting interferon for treatment of systemic lupus erythematosus (SLE or lupus), and mavrilimumab, a monoclonal antibody targeting GM?CSF for the treatment of rheumatoid arthritis (RA),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 
• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.